• DRAMP ID

    • DRAMP20909
    • Peptide Name

    • Ctry2459-H2 (Ctry2459 peptide derivative, His-rich)
    • Source

    • Synthetic construct( from a scorpion venom peptide library)
    • Family

    • Derived from the peptide Ctry2460
    • Gene

    • Not found
    • Sequence

    • FLGFLHHLF
    • Sequence Length

    • 9
    • UniProt Entry

    • No entry found
    • Protein Existence

    • Synthetic
    • Biological Activity

    • Antimicrobial, Antiviral
    • Target Organism

      • [Ref.23415044] Virus: Hepatitis C virus ( EC50 = 1.08 μg/ml ).
      • Cytotoxic: Huh7.5.1 cells (CC50>500 μg/ml)
    • Hemolytic Activity

      • [Ref.23415044] HC50 = 203.3 μg/ml against human red blood cells.
    • Cytotoxicity

      • [Ref.23415044] CC50>500 μg/ml against Huh7.5.1 cells
    • Binding Target

    • Not found
    • Linear/Cyclic

    • Linear
    • N-terminal Modification

    • Free
    • C-terminal Modification

    • Amidation
    • Nonterminal Modifications and Unusual Amino Acids

    • None
    • Stereochemistry

    • L
    • Structure

    • Not found
    • Structure Description

    • Not found
    • Helical Wheel Diagram

    • DRAMP20909 helical wheel diagram
    • PDB ID

    • None
    • Predicted Structure

    • There is no predicted structure for DRAMP20909.
    • Formula

    • C59H79N13O10
    • Absent Amino Acids

    • ACDEIKMNPQRSTVWY
    • Common Amino Acids

    • FL
    • Mass

    • 1130.36
    • PI

    • 6.92
    • Basic Residues

    • 2
    • Acidic Residues

    • 0
    • Hydrophobic Residues

    • 6
    • Net Charge

    • +2
    • Boman Index

    • 1532
    • Hydrophobicity

    • 1.444
    • Aliphatic Index

    • 130
    • Half Life

      • Mammalian:1.1 hour
      • Yeast:3 min
      • E.coli:2 min
    • Extinction Coefficient Cystines

    • 0
    • Absorbance 280nm

    • 0
    • Polar Residues

    • 1

DRAMP20909

    • Function

    • Inhibits hepatitis C virus(HCV) infection via inactivating infectious viral particle. However, it cannot suppress established infection because of the poor cellular uptake and restriction of endosomes.
  • ·Literature 1
    • Title

    • Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus.
    • Reference

    • Biomaterials. 2013 Apr;34(13):3511-22.
    • Author

    • Hong W, Zhang R, Di Z, He Y, Zhao Z, Hu J, Wu Y, Li W, Cao Z.